Company Overview
Snapshot
Founded in July 2011 by Iram Levit and Gil Levy, Lyra Medical operates with 1-10 employees. The company has secured additional funding from a high-profile private investors group in the US to advance its clinical studies and regulatory affairs for its pelvic organ prolapse treatment technology.
Business overview
Lyra Medical is a Health Tech & Life Sciences company focused on developing a safe, long-term solution for women suffering from pelvic organ prolapse. The company's core product, the Lyra system, utilizes Self-Retaining Support (SRS) technology for anterior vaginal wall, apex, and uterine prolapse. This platform also has potential applications in other pelvic organ disorders, including rectocele and urinary incontinence, as well as broader clinical areas like hernias. Lyra Medical serves the healthcare industry, targeting patients and providers with its medical device technology.
Strategic signal
In January 2016, Lyra Medical secured additional funding from a high-profile private investors group in the US. This investment is critical for expanding clinical studies and obtaining regulatory approvals (CE mark and AMAR) for its trans-vaginal implant, signaling a strong commitment to evidence-based market adoption and product launch in Israel and strategic EU markets.
Log in to access full profile ›Company Intelligence Q&A
- What is Lyra Medical's core technology?
- Lyra Medical develops Self-Retaining Support (SRS) technology, which is used in its flagship Lyra system for pelvic floor repair, specifically targeting anterior vaginal wall, apex, and uterine prolapse. This technology aims to provide a safe and long-term treatment solution.
- When was Lyra Medical founded and by whom?
- Lyra Medical was founded in July 2011 by co-founders Iram Levit, who serves as CEO, and Gil Levy, who serves as CMO.
- What is the primary focus of Lyra Medical's product development?
- Lyra Medical's primary focus is on developing a safe way to implant an organ-support mechanism for women suffering from pelvic organ prolapse, with potential applications extending to rectocele, urinary incontinence, and other hernia conditions.
- What is the status of Lyra Medical's regulatory approvals and market entry?
- Lyra Medical is in the process of obtaining EU and Israeli regulatory approval (CE mark and AMAR). Following these approvals, the company plans a product launch in Israel and strategic EU markets, supported by an international distribution agreement with an EU-based strategic partner.
- What clinical evidence supports Lyra Medical's technology?
- Lyra Medical has completed two clinical studies involving a total of 70 patients, which have shown excellent results for its Self-Retaining Support (SRS) technology.